Quarterly report pursuant to Section 13 or 15(d)

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

v3.24.1.1.u2
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS    
Revenue, net $ 255,000 $ 469,000
Cost of revenue 338,000 1,722,000
Gross deficit (83,000) (1,253,000)
Operating Expenses:    
Research and development 1,715,000 1,893,000
Sales and marketing 929,000 1,294,000
General and administrative 1,431,000 1,362,000
Total operating expenses 4,075,000 4,549,000
Loss from operations (4,158,000) (5,802,000)
Interest expense, net (1,265,000) (723,000)
Change in fair value of warrant liabilities 8,129,000 5,604,000
Other expense, net 1,000  
Income (loss) before provision for income taxes 2,707,000 (921,000)
Provision for income taxes 0 0
Net income (loss) 2,707,000 (921,000)
Deemed dividend on conversion of Series B preferred for common stock and repurchase of Series B preferred stock (5,842,000)  
Net loss attributable to common stockholders $ (3,135,000) $ (921,000)
Net loss per common share- basic (in dollars per share) $ (5.35) $ (79.84)
Net loss per common share- diluted (in dollars per share) $ (5.35) $ (79.84)
Weighted average number of common shares used in computing net loss per common share - Basic (in shares) 585,500 11,536
Weighted average number of common shares used in computing net loss per common share - Diluted (in shares) 585,500 11,536